NOVOBN:BMV
Novo
723,50 MXN
arrow_upward
+1,76%(+12,50) 1D
15. okt., 14:00:00 GMT -6 · MXN
search
Vsi simboli
| Simbol | Cena | Sprememba | Odstotna sprememba |
|---|
insights_autoGeneriranje najpomembnejših vpogledov za NOVOBN …
Odpri
728,00 MXN
Visoka
741,49 MXN
Nizka
720,00 MXN
Tržna kapitalizacija
133,83 mrd.
Povprečni promet
386,00
Promet
54,00
52-tedenski najvišji tečaj
1.149,99 MXN
52-tedenski najnižji tečaj
630,00 MXN
Št. zaposlenih
67 tis.
Odpri
728,00 MXN
Visoka
741,49 MXN
Nizka
720,00 MXN
Tržna kapitalizacija
133,83 mrd.
Povprečni promet
386,00
Promet
54,00
52-tedenski najvišji tečaj
1.149,99 MXN
52-tedenski najnižji tečaj
630,00 MXN
Št. zaposlenih
67 tis.
Novice
Iz spletnih virov in novičarskih partnerjev
Foreign Policy Journal
·
pred 50 minutami
Novo Nordisk (NYSE: NVO) Stock Price May Be 63% Undervalued As Buyback And Pipeline Catalysts Mount
TradingKey
·
pred 8 urami
Novo Nordisk A/S Stock (NVO) Moved Up by 3.38% on Oct 15: What Investors Need To Know
Traders Union
·
pred 12 urami
Why is Novo Nordisk stock up 3.2% today?
Traders Union
·
pred 18 urami
Novo Nordisk stock consolidates amid seller pressure near $38.39 resistance
Profil
Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark, and it became the highest valued company in Europe. Wikipedia
Vizitka: Novo
Generalni direktorMaziar Mike Doustdar
Št. zaposlenih66,7 tis.
Ustanovljeno1923
SedežBagsværd, Capital Region of Denmark, Danska
Sektor-
Spletno mestonovonordisk.com